CNR1 and Dyskinesia: For instance, CB1/CB2 agonists may interrupt excitotoxicity and reduce neuroinflammation in AD brains, modulators of endocannabinoid signaling may reduce hyperactivity in HD, while CB1 agonists could reduce dyskinesia in PD.